Clinical trials
Phase 4 Recurrence trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
29 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2004 | 3 |
| 2005 | 2 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 3 |
| 2009 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 1 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 1 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 18 |
| Terminated | 4 |
| Unknown status | 4 |
| Active, not recruiting | 2 |
| Recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| University of Wisconsin, Madison | 2 |
| Alameda County Medical Center | 1 |
| Amgen | 1 |
| Centre hospitalier de l'Université de Montréal (CHUM) | 1 |
| Clinical Directors Network | 1 |
| Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 1 |
| Genentech, Inc. | 1 |
| GlaxoSmithKline | 1 |
| Johns Hopkins University | 1 |
| Manhattan Medical Research Practice, PLLC | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Recurrence | 29 |
| Multiple Sclerosis | 3 |
| Schizophrenia | 3 |
| Leukemia | 2 |
| Lymphoma | 2 |
| Major Depressive Disorder | 2 |
| Tobacco Use Disorder | 2 |
| Anemia | 1 |
| Anxiety Disorders | 1 |
| Asthma | 1 |
Trials
Showing 1 to 25 of 29. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.